Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04234048 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
A Phase 1 study of Peripheral T-Cell Lymphoma and Cutaneous T Cell Lymphoma, sponsored by SciTech Development.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 46
- Enrollment target
- 10
- Study locations
NCT04234048: Recruiting Phase 1 study of Peripheral T-Cell Lymphoma and Cutaneous T Cell Lymphoma, sponsored by SciTech Development.
NCT04234048 is a Phase 1 study of Peripheral T-Cell Lymphoma and Cutaneous T Cell Lymphoma that is actively recruiting participants, run by SciTech Development. The registered enrollment target is 46 participants, below the 105-participant average among 34 other Peripheral T-Cell Lymphoma trials with a reported enrollment target (56% lower). The trial reports 10 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04234048, a Phase 1 study of Peripheral T-Cell Lymphoma and Cutaneous T Cell Lymphoma, is actively recruiting participants, sponsored by SciTech Development.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 46 participants
- Enrollment target
- 10
- Study locations
Study Summary
This study evaluates a fenretinide phospholipid suspension for the treatment of T-cell non-Hodgkin's lymphoma (NHL).
Primary Outcome
To determine the MTD of ST-001 nanoFenretinide (12.5mg/mL) for IV infusion in patients with CTCL and other T-cell NHL.
Conditions Studied
Interventions
- DRUG Fenretinide
Study Locations (10)
California
- City of Hope Medical Foundation - Duarte
- University of Southern California - Los Angeles
Michigan
- University of Michigan - Ann Arbor
- Barbara Ann Karmanos Cancer Institute Wayne State University - Detroit
Arizona
- Mayo Clinic Arizona - Scottsdale
Colorado
- University of Colorado Anschutz Medical Campus - Aurora
Illinois
- Northwestern University, Robert H. Lurie Comprehensive Cancer Center - Chicago
New York
- Columbia University - New York
Pennsylvania
- University of Pittsburgh Medical Center (UPMC) - Pittsburgh
Texas
- The University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2023-12-18 |
| Est. Completion | 2027-05-01 |
| Phase | Phase 1 |
What NCT04234048 shows while recruiting
NCT04234048 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 46 participants, a relatively small participant target, below the 105-participant average among 34 other Peripheral T-Cell Lymphoma trials with a reported enrollment target (56% lower).
The record links to 10 conditions, with Peripheral T-Cell Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which Fenretinide is the first listed.
NCT04234048 lists 10 locations in 8 states (California, Michigan, Arizona).
Frequently Asked Questions
What is clinical trial NCT04234048 about?
NCT04234048 is a clinical study titled "Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma". This study evaluates a fenretinide phospholipid suspension for the treatment of T-cell non-Hodgkin's lymphoma (NHL).
What is the current status of trial NCT04234048?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2023-12-18. Estimated completion is 2027-05-01.
What conditions does trial NCT04234048 study?
This clinical trial studies the following conditions: Peripheral T-Cell Lymphoma, Cutaneous T Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, T-Cell Lymphoma, Follicular T-Cell Lymphoma.
What interventions are being tested in trial NCT04234048?
The interventions under investigation include: Fenretinide (DRUG).
Who is sponsoring clinical trial NCT04234048?
This trial is sponsored by SciTech Development, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04234048 being conducted?
This trial has 10 study locations across Arizona, California, Colorado, Illinois, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peripheral T-Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04234048's enrollment target sits among peer trials
46 17th of 34 higher than 18 of 34 other Peripheral T-Cell Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Peripheral T-Cell Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)
RECRUITING · Phase 1
-
Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma
RECRUITING · Phase 1
-
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
RECRUITING · Phase 1
-
Evaluate the Safety and Clinical Activity of HH2853
RECRUITING · Phase 1
-
Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01890590 · 46 participants · NA
A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
- NCT03191149 · 46 participants · Phase 2
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- NCT03510208 · 46 participants · Phase 1
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
- NCT04048278 · 46 participants · Early Phase 1
Lidocaine Infusion in Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI